Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 7/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.46 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 4/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 4/20 | 0.45 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29478509 | 1.00 | PARP1 (0.46) | PARP1CHEK1PIM1RPS6KA3SRC | |
| SCHEMBL1012303 | 0.96 | SRC (0.52) | SRCEGFRKDR | |
| SCHEMBL1780281 | 0.96 | SRC (0.52) | SRCEGFRKDR | |
| SCHEMBL17854651 | 0.94 | PDE5A (0.47) | PARP1CHEK1PIM1RPS6KA3SRC | |
| SCHEMBL4380700 | 0.92 | SRC (0.49) | SRCEGFRKDR | |
| SCHEMBL17858844 | 0.90 | SLC2A1 (0.44) | PARP1CHEK1PIM1RPS6KA3SRC | |
| SCHEMBL20866206 | 0.90 | SLC2A1 (0.44) | PARP1CHEK1PIM1RPS6KA3SRC | |
| SCHEMBL27843811 | 0.89 | PARP1 (0.46) | PARP1CHEK1PIM1RPS6KA3SRC | |
| SCHEMBL1507502 | 0.85 | PARP1 (0.46) | PARP1CHEK1PIM1RPS6KA3SRC | |
| SCHEMBL7215875 | 0.84 | SRC (0.47) | SRCEGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115108999-B | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2023-11-03 | — | — | CN | claimed |
| CN-104945332-A | Preparation method of erlotinib | GUANGZHOU INST BIOMED & HEALTH | 2015-09-30 | — | — | CN | claimed |
| CN-104725327-A | Environment-friendly method for preparing high-yield erlotinib hydrochloride | UNIV SHANDONG | 2015-06-24 | — | — | CN | claimed |
| CN-104211648-A | Synthetic process method of erlotinib intermediate | TIANJIN CENTRAL PHARMACEUTICAL CO LTD | 2014-12-17 | — | — | CN | claimed |
| CN-104193688-A | Synthetic method for erlotinib intermediate | ESTEVE HUAYI PHARMACEUTICAL CO LTD | 2014-12-10 | — | — | CN | claimed |
| US-8133999-B2 | Process for preparation of 6, 7-bis(2-methoxyethoxy) quinazolin-4-one | UBE INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | claimed |
| EP-1650196-B1 | PROCESS FOR PRODUCING 6,7-BIS(2-METHOXYETHOXY)-QUINAZOLIN-4-ONE | UBE INDUSTRIES (JP) | 2011-03-30 | — | — | EP | claimed |
| US-20090253909-A1 | PROCESS FOR PREPARATION OF 6, 7-BIS (2-METHOXYETHOXY) QUINAZOLIN-4-ONE | UBE INDUSTRIES, LTD. (JP) | 2009-10-08 | — | — | US | claimed |
| US-20060276647-A1 | Process for producing 6, 7-bis (2-methoxyethoxy)-quinazolin-4-one | UBE INDUSTRIES, LTD (JP) | 2006-12-07 | — | — | US | claimed |
| EP-1650196-A1 | PROCESS FOR PRODUCING 6,7-BIS(2-METHOXYETHOXY)-QUINAZOLIN-4-ONE | Ube Industries, Ltd. (JP) | 2006-04-26 | — | — | EP | claimed |
| US-11935803-B2 | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-03-19 | — | — | US | disclosed |
| CN-114920704-B | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2023-11-03 | — | — | CN | disclosed |
| CN-115108999-B | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2023-11-03 | — | — | CN | disclosed |
| CN-115108999-A | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2022-09-27 | — | — | CN | disclosed |
| CN-112300082-B | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2022-04-26 | — | — | CN | disclosed |
| WO-2001021596-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |
| EP-0790986-B1 | ANILINE DERIVATIVES | ZENECA LTD (GB) | 1999-01-20 | — | — | EP | disclosed |
| US-5821246-A | USEFUL AS TYROSINE KINASE INHIBITORS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ZENECA LIMITED (GB) | 1998-10-13 | — | — | US | disclosed |
| EP-0790986-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996015118-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276647-A1 | Process for producing 6, 7-bis (2-methoxyethoxy)-quinazolin-4-one | CPS1, CYP3A4, RPS27A | PARP1 814/4885CHEK1 2734/4885PIM1 2104/4885 |
| US-20090253909-A1 | PROCESS FOR PREPARATION OF 6, 7-BIS (2-METHOXYETHOXY) QUINAZOLIN-4-ONE | CYP4F11, OGFR, CYP4B1 | PARP1 3577/4885CHEK1 2154/4885PIM1 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.